Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study
Yilin Chen(Sun Yat-sen University), Josh J. Carlson(University of Washington), Anirban Basu(National Bureau of Economic Research), Peter Martin(Northwestern University), Lurdes Y. T. Inoue(Institut de Médecine de la Reproduction)
Cited by 7
Related Papers
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
|Blood|2015|408
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
|Journal of Clinical Oncology|2009|340
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
|Journal of Clinical Oncology|2010|319